Evolent reaffirms FY2023 guidance; announces two new contract wins

Evolent Health, Inc.

Reaffirmed previously issued revenue and Adjusted EBITDA guidance for Q4 and full year 2023.
Secured new partner logo in the Southwest for its technology and services suite.
Cross-sold NIA services to a legacy Evolent client in the Northeast.

item 2.02 item 7.01 item 9.01

Evolent Health, Inc. filing history →

Source: SEC EDGAR

accession 0001628908-24-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.